

Erik J. MacLaren, PhD

(720) 737-3822

erik@galenmedicalwriting.com

www.galenmedicalwriting.com

www.linkedin.com/in/ejmaclaren/



Key Attributes

- Expertise in molecular biology, pharmacology, and neuroscience
- Extensive experience with the peer-reviewed publication process
- Excellent written and verbal communications skills
- Punctual, reliable, and organized

Experience

Freelance Medical Writer, 2013-present

Galen Medical Writing, Denver, CO

Research Associate, 2013-2014

Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO

Postdoctoral Fellow, 2009-2011

Centre for Stroke Recovery, Ottawa Hospital Research Institute, Ottawa, Canada

Postdoctoral Fellow, 2006-2009

Wellcome Trust Sanger Institute, Cambridge, United Kingdom

Postdoctoral Fellow, 2005-2006

University of Colorado Health Sciences Center, Aurora, CO

Education

PhD, Pharmacology, 2005

University of Colorado Health Sciences Center, Denver, CO

BS, Molecular Biology/Biochemistry, 1999

Marquette University, Milwaukee, WI

Professional Societies

American Medical Writers Association, 2014-present

- *Chapter Advisory Council Chairperson, National Board of Directors:* 2023-present
- *President, Rocky Mountain Chapter:* 2017-18; 2020-21
- *Treasurer, RMC:* 2016-2017
- *Membership Director, RMC:* 2015-2016

International Society for Medical Publication Professionals, 2017-present

Society for Technical Communication, 2016-2017

Professional Certificates

Certified Medical Publication Professional (CMPP): 2023-present

International Society for Medical Publication Professionals

Selected Publications

1. Rugo HS, Bardia A, Gradishar WJ, et al. Expert consensus on treating HR+/HER2-metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists. *Breast* 2025;82:104485. <https://www.ncbi.nlm.nih.gov/pubmed/40344957>
2. Sasu BJ, Opiteck GJ, Gopalakrishnan S, et al. Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells. *Mol Ther*. 2023;31(3):676–85. <https://www.ncbi.nlm.nih.gov/pubmed/36518079>
3. Mailankody S, Matous JV, Chhabra S, et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. *Nat Med*. 2023;29(2):422–9. <https://www.ncbi.nlm.nih.gov/pubmed/36690811>
4. Tam C, Pinilla-Ibarz J, Castillo CG, et al. Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL. *Blood Adv*. 2023;7(22):6819–28. <https://www.ncbi.nlm.nih.gov/pubmed/37722356>
5. Awan FT, Addison D, Alfraih F, et al. International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. *Blood Adv*. 2022;6(18):5516–25. <https://www.ncbi.nlm.nih.gov/pubmed/35790105>